Open AccessResults of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases
Author(s) -
Marybeth S. Hughes,
Jonathan S. Zager,
Mark B. Faries,
H. Richard Alexander,
Richard E. Royal,
Bradford J. Wood,
Junsung Choi,
Kevin McCluskey,
Eric D. Whitman,
Sanjiv S. Agarwala,
Gary P. Siskin,
Charles Nutting,
Mary Ann Toomey,
Carole C. Webb,
Tatiana Beresnev,
James F. Pingpank
Publication year - 2015
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-015-4968-3
Subject(s) - medicine , melphalan , randomized controlled trial , clinical endpoint , melanoma , surgical oncology , gastroenterology , surgery , chemotherapy , cancer research
There is no consensus for the treatment of melanoma metastatic to the liver. Percutaneous hepatic perfusion with melphalan (PHP-Mel) is a method of delivering regional chemotherapy selectively to the liver. In this study, we report the results of a multicenter, randomized controlled trial comparing PHP-Mel with best alternative care (BAC) for patients with ocular or cutaneous melanoma metastatic to the liver.